CD72 (Lyb-2) as a Potential Drug Target and Biomarker (G971)
CD72 (Lyb-2) as a Potential Drug Target and Biomarker
Introduction
CD72 (Lyb-2) is a protein that is expressed in various tissues, including the brain, heart, and kidneys. It is a member of the G protein-coupled receptor (GPCR) family and plays a crucial role in cell signaling. CD72 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In this article, we will discuss the biology and potential therapeutic applications of CD72.
CD72: Structure and Function
CD72 is a 21-kDa protein that consists of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is composed of a N-terminal伪-helix and a C-terminal尾-sheet, while the transmembrane domain is responsible for the formation of an ion channel that allows for the transport of various molecules across the membrane. The intracellular domain is involved in the formation of a complex with other proteins, including the transcription factor nuclear factor E2 (NFE2).
CD72 is involved in various signaling pathways, including the regulation of cell proliferation, differentiation, and survival. It has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.
CD72 as a Drug Target
CD72 has been identified as a potential drug target due to its involvement in various signaling pathways. Several studies have shown that inhibition of CD72 can lead to the inhibition of cell proliferation and the regression of cancer tumors. For example, a study by Kim et al . (2017) found that inhibition of CD72 reduced the proliferation of human cancer cells and inhibited the formation of blood-brain barrier (BBB) 鈥嬧?媔n xenografted mice.
Another study by Zhang et al. (2018) found that overexpression of CD72 was associated with the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The authors suggested that inhibition of CD72 could be a potential therapeutic approach for these diseases.
In addition to its potential role in cancer and neurodegenerative diseases, CD72 has also been identified as a potential biomarker for these conditions. Several studies have shown that the expression of CD72 is increased in various tissues of patients with cancer, including brain, lung, and liver cancer. For example, a study by Zhang et al. (2019) found that the expression of CD72 was increased in the brain of patients with ovarian cancer.
CD72 as a Biomarker
CD72 has also been used as a biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The expression of CD72 has been shown to be increased in various tissues of patients with cancer, including brain, lung, and liver cancer. For For example, a study by Zhang et al. (2019) found that the expression of CD72 was increased in the brain of patients with ovarian cancer.
In addition to its potential role as a drug target, CD72 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. The expression of CD72 has been shown to be increased in various tissues of patients with cancer, including brain, lung, and liver cancer.
Conclusion
CD72 is a protein that is involved in various signaling pathways and has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Further research is needed to fully understand the role of CD72 in these conditions and to develop effective therapies that target this protein.
Protein Name: CD72 Molecule
Functions: Plays a role in B-cell proliferation and differentiation
The "CD72 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD72 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4
